BioMarin Pharmaceutical Inc. (BMRN)
USD 55.89
(-5.53%)
USD 55.89
(-5.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 167.64 Million USD | 18.43% |
| 2022 | 141.56 Million USD | 320.91% |
| 2021 | -64.08 Million USD | -107.5% |
| 2020 | 854.02 Million USD | 3681.13% |
| 2019 | -23.84 Million USD | 69.11% |
| 2018 | -77.21 Million USD | 34.03% |
| 2017 | -117.04 Million USD | 81.43% |
| 2016 | -630.21 Million USD | -266.83% |
| 2015 | -171.79 Million USD | -28.24% |
| 2014 | -133.96 Million USD | 24.03% |
| 2013 | -176.35 Million USD | -54.23% |
| 2012 | -114.34 Million USD | -112.4% |
| 2011 | -53.83 Million USD | -126.16% |
| 2010 | 205.81 Million USD | 42276.02% |
| 2009 | -488 Thousand USD | -101.58% |
| 2008 | 30.83 Million USD | 295.1% |
| 2007 | -15.8 Million USD | 44.62% |
| 2006 | -28.53 Million USD | 61.58% |
| 2005 | -74.27 Million USD | 60.38% |
| 2004 | -187.44 Million USD | -147.29% |
| 2003 | -75.79 Million USD | 2.15% |
| 2002 | -77.46 Million USD | -14.58% |
| 2001 | -67.6 Million USD | -80.94% |
| 2000 | -37.36 Million USD | -33.1% |
| 1999 | -28.07 Million USD | -128.23% |
| 1998 | -12.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 106.08 Billion USD | -1.02% |
| 2024 Q1 | 88.66 Million USD | 335.15% |
| 2024 Q2 | 107.17 Million USD | 20.88% |
| 2023 Q4 | 20.37 Million USD | -49.54% |
| 2023 FY | 167.64 Million USD | 18.43% |
| 2023 Q2 | 56.04 Million USD | 10.2% |
| 2023 Q3 | 40.37 Million USD | -27.95% |
| 2023 Q1 | 50.85 Million USD | 20522.49% |
| 2022 Q1 | 120.79 Million USD | 308.64% |
| 2022 Q3 | -6.65 Million USD | -124.05% |
| 2022 Q4 | -249 Thousand USD | 96.26% |
| 2022 FY | 141.56 Million USD | 320.91% |
| 2022 Q2 | 27.66 Million USD | -77.1% |
| 2021 Q2 | 12.94 Million USD | -25.5% |
| 2021 Q4 | -57.89 Million USD | -58.65% |
| 2021 Q1 | 17.37 Million USD | -21.39% |
| 2021 FY | -64.08 Million USD | -107.5% |
| 2021 Q3 | -36.49 Million USD | -382.0% |
| 2020 Q2 | -29.18 Million USD | -135.86% |
| 2020 FY | 854.02 Million USD | 3681.13% |
| 2020 Q1 | 81.38 Million USD | 441.67% |
| 2020 Q4 | 22.09 Million USD | -97.18% |
| 2020 Q3 | 784.8 Million USD | 2789.25% |
| 2019 Q2 | -37.43 Million USD | 33.71% |
| 2019 Q1 | -56.47 Million USD | -1447.21% |
| 2019 Q4 | 15.02 Million USD | -72.7% |
| 2019 FY | -23.84 Million USD | 69.11% |
| 2019 Q3 | 55.03 Million USD | 247.02% |
| 2018 Q4 | -3.65 Million USD | 71.08% |
| 2018 Q2 | -16.79 Million USD | 61.97% |
| 2018 FY | -77.21 Million USD | 34.03% |
| 2018 Q3 | -12.62 Million USD | 24.85% |
| 2018 Q1 | -44.14 Million USD | 14.09% |
| 2017 Q3 | -12.52 Million USD | 65.99% |
| 2017 FY | -117.04 Million USD | 81.43% |
| 2017 Q1 | -16.29 Million USD | 82.04% |
| 2017 Q4 | -51.39 Million USD | -310.25% |
| 2017 Q2 | -36.83 Million USD | -126.11% |
| 2016 FY | -630.21 Million USD | -266.83% |
| 2016 Q4 | -90.72 Million USD | -111.98% |
| 2016 Q3 | -42.79 Million USD | 89.9% |
| 2016 Q2 | -423.56 Million USD | -397.47% |
| 2016 Q1 | -85.14 Million USD | -224.08% |
| 2015 Q2 | -81.98 Million USD | -21.46% |
| 2015 Q4 | 68.61 Million USD | 175.46% |
| 2015 Q3 | -90.92 Million USD | -10.9% |
| 2015 FY | -171.79 Million USD | -28.24% |
| 2015 Q1 | -67.5 Million USD | 3.29% |
| 2014 Q4 | -69.79 Million USD | -1037.5% |
| 2014 FY | -133.96 Million USD | 24.03% |
| 2014 Q1 | -38.11 Million USD | 38.51% |
| 2014 Q3 | 7.44 Million USD | 122.22% |
| 2014 Q2 | -33.5 Million USD | 12.1% |
| 2013 Q2 | -21.53 Million USD | 45.91% |
| 2013 Q1 | -39.81 Million USD | 24.9% |
| 2013 Q4 | -61.99 Million USD | -16.92% |
| 2013 FY | -176.35 Million USD | -54.23% |
| 2013 Q3 | -53.02 Million USD | -146.23% |
| 2012 Q3 | -5.35 Million USD | 83.26% |
| 2012 Q4 | -53.01 Million USD | -889.58% |
| 2012 FY | -114.34 Million USD | -112.4% |
| 2012 Q1 | -23.97 Million USD | 10.33% |
| 2012 Q2 | -32 Million USD | -33.51% |
| 2011 Q2 | -5.07 Million USD | -16.15% |
| 2011 Q3 | -17.65 Million USD | -247.71% |
| 2011 Q4 | -26.73 Million USD | -51.45% |
| 2011 FY | -53.83 Million USD | -126.16% |
| 2011 Q1 | -4.37 Million USD | 64.14% |
| 2010 Q3 | 217.33 Million USD | 45662.68% |
| 2010 Q2 | -477 Thousand USD | -141.44% |
| 2010 Q1 | 1.15 Million USD | -75.57% |
| 2010 FY | 205.81 Million USD | 42276.02% |
| 2010 Q4 | -12.18 Million USD | -105.61% |
| 2009 FY | -488 Thousand USD | -101.58% |
| 2009 Q1 | -13.15 Million USD | -153.67% |
| 2009 Q4 | 4.71 Million USD | -29.05% |
| 2009 Q3 | 6.64 Million USD | 406.1% |
| 2009 Q2 | 1.31 Million USD | 109.98% |
| 2008 Q3 | 829 Thousand USD | -78.24% |
| 2008 Q2 | 3.81 Million USD | 125.98% |
| 2008 Q4 | 24.5 Million USD | 2856.09% |
| 2008 Q1 | 1.68 Million USD | -34.4% |
| 2008 FY | 30.83 Million USD | 295.1% |
| 2007 Q2 | -3.86 Million USD | 58.42% |
| 2007 FY | -15.8 Million USD | 44.62% |
| 2007 Q1 | -9.29 Million USD | 10.57% |
| 2007 Q4 | 2.57 Million USD | 149.27% |
| 2007 Q3 | -5.21 Million USD | -34.99% |
| 2006 Q1 | -9.78 Million USD | 34.78% |
| 2006 FY | -28.53 Million USD | 61.58% |
| 2006 Q4 | -10.39 Million USD | -47.68% |
| 2006 Q3 | -7.03 Million USD | -431.02% |
| 2006 Q2 | -1.32 Million USD | 86.45% |
| 2005 Q4 | -14.99 Million USD | 3.1% |
| 2005 Q2 | -21.34 Million USD | 4.98% |
| 2005 Q1 | -22.45 Million USD | 72.75% |
| 2005 Q3 | -15.47 Million USD | 27.48% |
| 2005 FY | -74.27 Million USD | 60.38% |
| 2004 FY | -187.44 Million USD | -147.29% |
| 2004 Q3 | -29.47 Million USD | 46.98% |
| 2004 Q4 | -82.42 Million USD | -179.61% |
| 2004 Q2 | -55.59 Million USD | -178.76% |
| 2004 Q1 | -19.94 Million USD | 22.47% |
| 2003 Q1 | -19.68 Million USD | -1.83% |
| 2003 FY | -75.79 Million USD | 2.15% |
| 2003 Q4 | -25.72 Million USD | -20.84% |
| 2003 Q3 | -21.29 Million USD | -134.04% |
| 2003 Q2 | -9.09 Million USD | 53.78% |
| 2002 Q3 | -17.1 Million USD | -18.72% |
| 2002 Q4 | -19.33 Million USD | -12.98% |
| 2002 FY | -77.46 Million USD | -14.58% |
| 2002 Q1 | -26.6 Million USD | 23.82% |
| 2002 Q2 | -14.41 Million USD | 45.83% |
| 2001 FY | -67.6 Million USD | -80.94% |
| 2001 Q4 | -34.92 Million USD | -217.04% |
| 2001 Q3 | -11.01 Million USD | 7.97% |
| 2001 Q2 | -11.96 Million USD | -23.39% |
| 2001 Q1 | -9.7 Million USD | 6.68% |
| 2000 Q3 | -8.14 Million USD | -14.99% |
| 2000 Q4 | -10.39 Million USD | -27.57% |
| 2000 Q2 | -7.08 Million USD | 39.62% |
| 2000 Q1 | -11.73 Million USD | -29.37% |
| 2000 FY | -37.36 Million USD | -33.1% |
| 1999 FY | -28.07 Million USD | -128.23% |
| 1999 Q2 | -6.8 Million USD | 65.48% |
| 1999 Q3 | -7.6 Million USD | -11.76% |
| 1999 Q1 | -19.7 Million USD | 0.0% |
| 1999 Q4 | -9.07 Million USD | -19.37% |
| 1998 FY | -12.3 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -51.92 Million USD | 422.86% |
| Jaguar Health, Inc. | -41.3 Million USD | 505.92% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 209.578% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 408.046% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 138.08% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -221.442% |
| ContextLogic Inc. | -317 Million USD | 152.885% |
| MiMedx Group, Inc. | 67.43 Million USD | -148.588% |
| MEI Pharma, Inc. | 17.77 Million USD | -842.991% |
| AlloVir, Inc. | -190.41 Million USD | 188.041% |
| Novavax, Inc. | -545.06 Million USD | 130.757% |
| Aptorum Group Limited | -2.82 Million USD | 6035.078% |
| Ardelyx, Inc. | -66.06 Million USD | 353.75% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 181.668% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 427.694% |
| Vaxcyte, Inc. | -402.26 Million USD | 141.675% |
| Precigen, Inc. | -95.9 Million USD | 274.805% |
| Pharming Group N.V. | -10.54 Million USD | 1689.353% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 183.161% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 783.066% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 768.148% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 178.996% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 1003.937% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 788.783% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 788.783% |
| Bicycle Therapeutics plc | -180.66 Million USD | 192.794% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 165.021% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 715.482% |
| Acelyrin, Inc. | -381.64 Million USD | 143.927% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 548.969% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 591.613% |
| Senti Biosciences, Inc. | -92.91 Million USD | 280.421% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 260.121% |
| AbCellera Biologics Inc. | -146.39 Million USD | 214.513% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 577.077% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 193.629% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 2607.779% |
| Chimerix, Inc. | -82.09 Million USD | 304.209% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 670.959% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 926.204% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 475.858% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 428.342% |
| Elevation Oncology, Inc. | -45.7 Million USD | 466.806% |
| Alkermes plc | 355.75 Million USD | 52.877% |
| Fortress Biotech, Inc. | -60.63 Million USD | 376.473% |
| Fortress Biotech, Inc. | -60.63 Million USD | 376.473% |
| Agenus Inc. | -245.76 Million USD | 168.215% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 305.498% |
| Dyadic International, Inc. | -6.79 Million USD | 2567.014% |
| ImmuCell Corporation | -5.77 Million USD | 3003.146% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 18010.791% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 248.41% |
| Lantern Pharma Inc. | -15.96 Million USD | 1150.306% |
| Immix Biopharma, Inc. | -15.42 Million USD | 1186.766% |
| Incyte Corporation | 597.59 Million USD | 71.947% |
| IO Biotech, Inc. | -86.08 Million USD | 294.748% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 387.59% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 981.003% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 384.228% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 201.866% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 2072.062% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 328.564% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 144.869% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 129.265% |
| NextCure, Inc. | -62.72 Million USD | 367.278% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 1778.8% |
| Onconetix, Inc. | -37.4 Million USD | 548.133% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 524.643% |
| Opthea Limited | -220.24 Million USD | 176.119% |
| PDS Biotechnology Corporation | -42.94 Million USD | 490.397% |
| PureTech Health plc | -65.69 Million USD | 355.179% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 327.192% |
| Seer, Inc. | -86.27 Million USD | 294.31% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 1336695.26% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 616.069% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 1382.487% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 689.22% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 391.491% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 369.288% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 226.531% |
| ChromaDex Corporation | -4.93 Million USD | 3494.998% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 4772.38% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 264.245% |
| CRISPR Therapeutics AG | -153.61 Million USD | 209.137% |
| Precision BioSciences, Inc. | -61.31 Million USD | 373.398% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 204.174% |
| Innoviva, Inc. | 179.72 Million USD | 6.72% |
| Summit Therapeutics Inc. | -614.92 Million USD | 127.263% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 350.235% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 354.915% |
| ESSA Pharma Inc. | -26.58 Million USD | 730.663% |
| GlycoMimetics, Inc. | -36.89 Million USD | 554.33% |
| GT Biopharma, Inc. | -7.59 Million USD | 2306.726% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 169.458% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -134.764% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 441.297% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 1785.256% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 168.261% |
| Aptose Biosciences Inc. | -51.2 Million USD | 427.387% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 270.548% |
| Soligenix, Inc. | -6.14 Million USD | 2830.05% |
| Century Therapeutics, Inc. | -136.67 Million USD | 222.661% |
| Kura Oncology, Inc. | -152.63 Million USD | 209.837% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 287.905% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 1690.862% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -29547.019% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 29563.093% |
| Autolus Therapeutics plc | -208.38 Million USD | 180.45% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 333.171% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 336.803% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 873.699% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 174.426% |
| GRI Bio, Inc. | -13.03 Million USD | 1385.917% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 4154.706% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 235.106% |
| IGM Biosciences, Inc. | -246.41 Million USD | 168.033% |
| INmune Bio, Inc. | -30 Million USD | 658.668% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 251.634% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 497.322% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1150.298% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 1161.381% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 380.883% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 265.711% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 160.713% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 170.471% |
| Verastem, Inc. | -87.36 Million USD | 291.886% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 409.377% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 203.91% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 243.706% |
| Histogen Inc. | -10.62 Million USD | 1678.43% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 1273.429% |
| Surrozen, Inc. | -43.04 Million USD | 489.492% |
| Organovo Holdings, Inc. | -14.67 Million USD | 1242.696% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 3395.539% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 420.306% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 763.599% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 722.336% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 2106.022% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 210.961% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 442.65% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 663.987% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 1709.232% |
| Apollomics, Inc. | -172.6 Million USD | 197.129% |
| Amarin Corporation plc | -59.11 Million USD | 383.606% |
| Mesoblast Limited | -87.95 Million USD | 290.601% |
| Turnstone Biologics Corp. | -55.2 Million USD | 403.705% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 214.074% |
| Synaptogenix, Inc. | -6.03 Million USD | 2876.267% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 1134.335% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 314.874% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 3598.825% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 2095.252% |
| Exelixis, Inc. | 207.76 Million USD | 19.31% |
| Better Therapeutics, Inc. | -39.76 Million USD | 521.642% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 216.462% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 131.713% |
| NLS Pharmaceutics AG | -12.17 Million USD | 1477.297% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 2250.759% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 645.205% |
| Gritstone bio, Inc. | -138.49 Million USD | 221.052% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 360.056% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 4291.177% |
| Avid Bioservices, Inc. | -140.75 Million USD | 219.106% |
| Insmed Incorporated | -749.56 Million USD | 122.366% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 1203.689% |
| MediWound Ltd. | -6.71 Million USD | 2596.203% |
| OmniAb, Inc. | -50.61 Million USD | 431.19% |
| Alector, Inc. | -130.39 Million USD | 228.571% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 247.414% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 423.346% |
| Zai Lab Limited | -334.62 Million USD | 150.1% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 151.745% |
| Aura Biosciences, Inc. | -76.4 Million USD | 319.408% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 171.45% |
| Immunic, Inc. | -93.61 Million USD | 279.085% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 223.365% |
| Veracyte, Inc. | -74.4 Million USD | 325.317% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 2284.143% |
| FibroGen, Inc. | -284.23 Million USD | 158.982% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 739.086% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 2494.282% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 990.181% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 59.587% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 843.272% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -240.251% |
| TG Therapeutics, Inc. | 12.67 Million USD | -1222.956% |
| Galecto, Inc. | -38.34 Million USD | 537.156% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 988.609% |
| Fortrea Holdings Inc. | -3.4 Million USD | 5030.735% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 232.375% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 1062.868% |
| XBiotech Inc. | -24.55 Million USD | 782.677% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 360.056% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 367.462% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 270.326% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 882.401% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 403.743% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 127.635% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 345.616% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 294554.983% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 174.003% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 852.868% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 176.303% |
| NexImmune, Inc. | -32.34 Million USD | 618.312% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 3271.146% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 1293.552% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 95.76% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 792.147% |
| Scopus BioPharma Inc. | -11.6 Million USD | 1543.992% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 243.534% |
| Ainos, Inc. | -13.77 Million USD | 1317.417% |
| Pluri Inc. | -20.88 Million USD | 902.59% |
| Prothena Corporation plc | -147.02 Million USD | 214.022% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 247.224% |
| Celularity Inc. | -196.29 Million USD | 185.405% |
| Rallybio Corporation | -74.56 Million USD | 324.834% |
| Cue Biopharma, Inc. | -50.73 Million USD | 430.446% |
| MeiraGTx Holdings plc | -84.02 Million USD | 299.513% |
| Omeros Corporation | -117.81 Million USD | 242.298% |
| Humacyte, Inc. | -110.77 Million USD | 251.337% |
| Immunocore Holdings plc | -55.28 Million USD | 403.227% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 1032.19% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 831.085% |
| Blueprint Medicines Corporation | -506.98 Million USD | 133.067% |
| CalciMedica, Inc. | -34.35 Million USD | 587.95% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 347.721% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 218.557% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 201.119% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 159.185% |
| Pulmatrix, Inc. | -14.12 Million USD | 1287.203% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 576.332% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 302.867% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 134.84% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 259.858% |
| Cytokinetics, Incorporated | -526.24 Million USD | 131.857% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 564.841% |
| Nutriband Inc. | -5.48 Million USD | 3156.252% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 514.758% |
| Vor Biopharma Inc. | -117.86 Million USD | 242.237% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 96.145% |
| Evogene Ltd. | -23.87 Million USD | 802.06% |
| ProKidney Corp. | -35.46 Million USD | 572.666% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 239.981% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 2236.86% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 126.064% |
| CorMedix Inc. | -46.33 Million USD | 461.778% |
| BioLineRx Ltd. | -60.61 Million USD | 376.578% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 264.771% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 508.233% |
| Atai Life Sciences N.V. | -40.22 Million USD | 516.779% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 307.867% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 321.985% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 157.375% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 701.395% |
| MediciNova, Inc. | -8.57 Million USD | 2055.838% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 235.99% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 2101.293% |
| GeoVax Labs, Inc. | -25.96 Million USD | 745.614% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 170.075% |
| Biomea Fusion, Inc. | -117.25 Million USD | 242.975% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 126.755% |
| Mereo BioPharma Group plc | -29.46 Million USD | 668.944% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 209.456% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 180.075% |
| Absci Corporation | -110.56 Million USD | 251.624% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 656.036% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 266.253% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 171.055% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -1090.322% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 186.88% |
| Allakos Inc. | -185.7 Million USD | 190.277% |
| Imunon, Inc. | -19.51 Million USD | 959.058% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 272.235% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -57.947% |
| BioAtla, Inc. | -123.46 Million USD | 235.787% |
| NLS Pharmaceutics AG | -12.17 Million USD | 1477.297% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 1142.698% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 151.226% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 553.72% |
| XOMA Corporation | -40.83 Million USD | 510.583% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 264.568% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 241.457% |
| aTyr Pharma, Inc. | -50.38 Million USD | 432.702% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 291.203% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 210.468% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 170.518% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 577.363% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 2171.753% |
| Akari Therapeutics, Plc | -10 Million USD | 1775.11% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 249108.541% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 40.466% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 2615.342% |
| UroGen Pharma Ltd. | -102.24 Million USD | 263.966% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 256.981% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 2255.6% |
| Orgenesis Inc. | -55.36 Million USD | 402.821% |
| Entera Bio Ltd. | -8.88 Million USD | 1985.983% |
| GH Research PLC | -35.58 Million USD | 571.085% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 904.439% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 316.629% |
| Xencor, Inc. | -126.08 Million USD | 232.96% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 4551.892% |
| Replimune Group, Inc. | -215.79 Million USD | 177.688% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 888.304% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -6581.746% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 2615.342% |
| Portage Biotech Inc. | -75.33 Million USD | 322.521% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 2101.293% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 273.447% |
| OncoCyte Corporation | -27.78 Million USD | 703.452% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 1349.477% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 1607.393% |
| Purple Biotech Ltd. | -19.88 Million USD | 943.285% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 2488.446% |
| scPharmaceuticals Inc. | -54.81 Million USD | 405.866% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 1057.635% |
| HilleVax, Inc. | -123.56 Million USD | 235.672% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 1758.702% |
| Tharimmune, Inc. | -9.31 Million USD | 1898.941% |
| Genprex, Inc. | -30.86 Million USD | 643.236% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 171.059% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 657.071% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 9507.688% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 3265.493% |
| OKYO Pharma Limited | -16.82 Thousand USD | 996476.919% |
| Savara Inc. | -54.69 Million USD | 406.492% |
| Curis, Inc. | -47.41 Million USD | 453.584% |
| Daré Bioscience, Inc. | -30.16 Million USD | 655.826% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 1185.426% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 3110.325% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 662.284% |
| BeiGene, Ltd. | -881.7 Million USD | 119.014% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 887.287% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 138.418% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 312.33% |
| Erasca, Inc. | -125.04 Million USD | 234.071% |
| bluebird bio, Inc. | -211.91 Million USD | 179.11% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 3452.567% |
| DBV Technologies S.A. | -72.72 Million USD | 330.516% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 3452.567% |
| Moderna, Inc. | -4.71 Billion USD | 103.556% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 517.474% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 3044.24% |
| Molecular Templates, Inc. | -8.12 Million USD | 2163.577% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 377.613% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 250.491% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 223.859% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 449.851% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 218.537% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 187.129% |
| MacroGenics, Inc. | -9.05 Million USD | 1950.795% |
| RenovoRx, Inc. | -10.23 Million USD | 1738.438% |
| Adicet Bio, Inc. | -142.65 Million USD | 217.515% |
| Prime Medicine, Inc. | -198.13 Million USD | 184.612% |
| Aditxt, Inc. | -32.38 Million USD | 617.729% |
| Adagene Inc. | -18.94 Million USD | 984.84% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2392.825% |
| Quantum-Si incorporated | -95.96 Million USD | 274.703% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 240.844% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 1250.005% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -26.687% |
| SciSparc Ltd. | -5.12 Million USD | 3373.038% |
| Vericel Corporation | -3.18 Million USD | 5368.542% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 139509.084% |
| Minerva Neurosciences, Inc. | -30 Million USD | 658.717% |
| Generation Bio Co. | -126.61 Million USD | 232.408% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 329.994% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 303.349% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 163.952% |
| Invivyd, Inc. | -198.64 Million USD | 184.395% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 149.023% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 2029.933% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -635.092% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 1797.843% |
| 2seventy bio, Inc. | -217.57 Million USD | 177.053% |
| ADMA Biologics, Inc. | -28.23 Million USD | 693.665% |
| Clene Inc. | -49.5 Million USD | 438.649% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 852.192% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 439.129% |
| GeoVax Labs, Inc. | -25.96 Million USD | 745.614% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 151.101% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 615.151% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -637.874% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 269.695% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 324.262% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 204.254% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 127.257% |
| Evaxion Biotech A/S | -22.12 Million USD | 857.718% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 307.646% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 183.794% |
| Trevena, Inc. | -40.28 Million USD | 516.106% |
| Surrozen, Inc. | -43.04 Million USD | 489.492% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 342.493% |
| Cingulate Inc. | -23.53 Million USD | 812.324% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 2525.42% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 520.585% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 2274.194% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 285.839% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 373.545% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 381.742% |
| Clearmind Medicine Inc. | -11.95 Million USD | 1502.297% |
| Kronos Bio, Inc. | -112.67 Million USD | 248.789% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 342.272% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 6610107.767% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 295.174% |
| Statera Biopharma, Inc. | -174.4 Million USD | 196.122% |
| ImmunityBio, Inc. | -583.19 Million USD | 128.746% |
| Korro Bio, Inc. | -81.17 Million USD | 306.531% |
| Kineta, Inc. | -14.09 Million USD | 1289.056% |
| BioVie Inc. | -32.12 Million USD | 621.925% |
| Codexis, Inc. | -76.24 Million USD | 319.891% |
| Celularity Inc. | -196.29 Million USD | 185.405% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 178.146% |
| Celcuity Inc. | -63.77 Million USD | 362.852% |
| Virax Biolabs Group Limited | -6.73 Million USD | 2589.702% |
| Cibus, Inc. | -267.62 Million USD | 162.641% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 515.724% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 568.138% |
| IN8bio, Inc. | -30 Million USD | 658.686% |
| Kodiak Sciences Inc. | -260.49 Million USD | 164.357% |
| Annexon, Inc. | -134.23 Million USD | 224.887% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 243.085% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 373.804% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 631.464% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 145.769% |
| Eyenovia, Inc. | -27.26 Million USD | 714.961% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -676.458% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 31435.514% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 319.419% |
| Arcellx, Inc. | -70.69 Million USD | 337.155% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 504.539% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 225.28% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 658.128% |
| Moolec Science SA | -51.78 Million USD | 423.708% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 420.11% |
| Geron Corporation | -184.12 Million USD | 191.049% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 499.402% |
| Royalty Pharma plc | 1.13 Billion USD | 85.227% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 223.308% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 1985.388% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 889.169% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 197.655% |
| Humacyte, Inc. | -110.77 Million USD | 251.337% |
| Structure Therapeutics Inc. | -89.62 Million USD | 287.062% |
| 89bio, Inc. | -142.18 Million USD | 217.903% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 343.105% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 1715.544% |
| Genelux Corporation | -28.29 Million USD | 692.448% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 676.793% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 194.651% |
| Notable Labs, Ltd. | -11.26 Million USD | 1588.326% |
| Liquidia Corporation | -78.5 Million USD | 313.555% |
| Mustang Bio, Inc. | -51.6 Million USD | 424.881% |
| Immunovant, Inc. | -259.33 Million USD | 164.644% |
| Quantum-Si incorporated | -95.96 Million USD | 274.703% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 330.127% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 964.997% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 274.648% |
| Acasti Pharma Inc. | -12.85 Million USD | 1404.326% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 846.487% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 1150.298% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 191.914% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 3997.346% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 1444.387% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 668.462% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 529.991% |
| PepGen Inc. | -78.62 Million USD | 313.218% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 663.153% |
| United Therapeutics Corporation | 984.8 Million USD | 82.977% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 853.122% |
| Solid Biosciences Inc. | -96.01 Million USD | 274.603% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 3598.825% |
| Immuneering Corporation | -53.47 Million USD | 413.521% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 3395.539% |
| Silo Pharma, Inc. | -3.7 Million USD | 4630.11% |
| Belite Bio, Inc | -31.63 Million USD | 629.985% |
| XOMA Corporation | -40.83 Million USD | 510.583% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 408.369% |
| Bionomics Limited | -15.49 Billion USD | 101.082% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 299.613% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 674.973% |
| uniQure N.V. | -308.47 Million USD | 154.346% |
| Cassava Sciences, Inc. | -97.21 Million USD | 272.444% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2392.825% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 235.822% |
| Forte Biosciences, Inc. | -31.47 Million USD | 632.612% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 2144.027% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 676.734% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 31435.514% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 739.086% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 1116.955% |
| Altimmune, Inc. | -88.44 Million USD | 289.543% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 210.595% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 674.973% |
| Compugen Ltd. | -18.75 Million USD | 993.916% |
| Peak Bio, Inc. | -1259.26 USD | 13313077.463% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 464.058% |
| Benitec Biopharma Inc. | -21.75 Million USD | 870.746% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 149.483% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 302.094% |
| Zura Bio Limited | -60.36 Million USD | 377.742% |
| PolyPid Ltd. | -23.86 Million USD | 802.472% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 1165.631% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 302.094% |
| Instil Bio, Inc. | -156.08 Million USD | 207.405% |
| argenx SE | -295.05 Million USD | 156.819% |
| Immunome, Inc. | -106.8 Million USD | 256.962% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 494.515% |
| Verona Pharma plc | -54.36 Million USD | 408.347% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 267.784% |
| Shattuck Labs, Inc. | -87.29 Million USD | 292.038% |
| CervoMed Inc. | -2.17 Million USD | 7818.914% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 234.492% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 1358.974% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 484.904% |
| Moolec Science SA | -51.78 Million USD | 423.708% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 969609.702% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 224.074% |
| AnaptysBio, Inc. | -163.61 Million USD | 202.461% |
| Design Therapeutics, Inc. | -66.86 Million USD | 350.733% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 305.917% |
| NeurAxis, Inc. | -14.62 Million USD | 1246.159% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 542.545% |
| Lumos Pharma, Inc. | -34.03 Million USD | 592.581% |
| Achilles Therapeutics plc | -69.66 Million USD | 340.645% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 267.784% |
| 180 Life Sciences Corp. | -19.93 Million USD | 940.953% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -5471.841% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 6610107.767% |
| Nutriband Inc. | -5.48 Million USD | 3156.252% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 266.485% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 444.899% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 317.464% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 593.509% |
| MoonLake Immunotherapeutics | -36 Million USD | 565.587% |
| Palisade Bio, Inc. | -12.3 Million USD | 1462.967% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 497.98% |
| Beam Therapeutics Inc. | -132.52 Million USD | 226.499% |
| Neurogene Inc. | -36.31 Million USD | 561.616% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 202.589% |
| AEON Biopharma, Inc. | -52.55 Million USD | 418.984% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 270.81% |
| Sesen Bio, Inc. | -19.88 Million USD | 943.115% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 334.193% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 1439.671% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 137.755% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 250.265% |
| Athira Pharma, Inc. | -117.67 Million USD | 242.468% |
| Vaccinex, Inc. | -20.25 Million USD | 927.836% |
| HCW Biologics Inc. | -24.99 Million USD | 770.734% |
| XOMA Corporation | -40.83 Million USD | 510.583% |
| Nektar Therapeutics | -276.05 Million USD | 160.729% |
| Arvinas, Inc. | -367.3 Million USD | 145.643% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 249108.541% |
| Merus N.V. | -154.93 Million USD | 208.201% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 272.071% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 634.156% |
| Rezolute, Inc. | -68.45 Million USD | 344.884% |
| Clene Inc. | -49.5 Million USD | 438.649% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 1186.947% |
| BeyondSpring Inc. | -21.02 Million USD | 897.322% |
| Synlogic, Inc. | -57.28 Million USD | 392.666% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 1508.663% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 1648.541% |
| Peak Bio, Inc. | -1259.26 USD | 13313077.463% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 548.633% |
| Krystal Biotech, Inc. | 10.93 Million USD | -1433.525% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 217.153% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 151.567% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 3729.493% |
| MannKind Corporation | -11.93 Million USD | 1504.297% |
| Ikena Oncology, Inc. | -68.16 Million USD | 345.936% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 897.74% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 280.393% |
| Gossamer Bio, Inc. | -179.81 Million USD | 193.231% |
| CohBar, Inc. | -11.96 Million USD | 1501.466% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 750.089% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 656.036% |
| Legend Biotech Corporation | -518.25 Million USD | 132.348% |
| Mural Oncology plc | -207.44 Million USD | 180.813% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 235.072% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 1016.608% |
| Disc Medicine, Inc. | -76.42 Million USD | 319.347% |
| Champions Oncology, Inc. | -7.27 Million USD | 2404.082% |
| REGENXBIO Inc. | -263.49 Million USD | 163.624% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 1679.608% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 452.9% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 541.363% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 267.372% |
| Vaxart, Inc. | -82.46 Million USD | 303.292% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -50128.755% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 546.547% |
| Cellectis S.A. | -101.05 Million USD | 265.888% |
| Longeveron Inc. | -21.41 Million USD | 882.912% |
| Repare Therapeutics Inc. | -93.79 Million USD | 278.734% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 131.278% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 335.559% |
| Revolution Medicines, Inc. | -436.36 Million USD | 138.418% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 2651.286% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 643.878% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 341.797% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 358.983% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 1808.745% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 95.368% |
| Denali Therapeutics Inc. | -145.22 Million USD | 215.439% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 139509.084% |
| Veru Inc. | -93.15 Million USD | 279.968% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 720.241% |
| Cingulate Inc. | -23.53 Million USD | 812.324% |
| Passage Bio, Inc. | -102.06 Million USD | 264.258% |
| Context Therapeutics Inc. | -23.96 Million USD | 799.564% |
| Exicure, Inc. | -16.91 Million USD | 1091.161% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 188.74% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 543.928% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 2676.251% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 190.777% |
| Nuvalent, Inc. | -126.21 Million USD | 232.821% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 1694.242% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 292.964% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 648.864% |
| OmniAb, Inc. | -50.61 Million USD | 431.19% |
| Anew Medical, Inc. | 1.34 Million USD | -12353.895% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 1144.843% |
| Lipocine Inc. | -16.35 Million USD | 1125.221% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 352.5% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 363.282% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 497.322% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 449.501% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 945.368% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 130.96% |
| Ocugen, Inc. | -63.07 Million USD | 365.774% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 275.119% |
| Q32 Bio Inc. | -112.96 Million USD | 248.41% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 1075.134% |
| Alumis Inc. Common Stock | -154.99 Million USD | 208.163% |
| Equillium, Inc. | -13.33 Million USD | 1357.18% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 377.714% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 2198.754% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 989.306% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 383.75% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 246.38% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 1012.207% |
| Dominari Holdings Inc. | -22.88 Million USD | 832.65% |
| Edesa Biotech, Inc. | -8.37 Million USD | 2101.871% |
| vTv Therapeutics Inc. | -20.25 Million USD | 927.877% |
| Bio-Techne Corporation | 168.1 Million USD | 0.274% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 147.615% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -30.106% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 237.603% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 541.88% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 248.83% |
| Nkarta, Inc. | -117.5 Million USD | 242.675% |
| BioCardia, Inc. | -11.57 Million USD | 1548.838% |
| Iterum Therapeutics plc | -38.37 Million USD | 536.905% |